d gaser
30 Mar 2016
Re: Flutiform It appears things are moving forward with the new business format .BE HAPPYDAVE Vectura Group plc Director disclosures Chippenham, UK - 23 March 2016: As announced on 16 March 2016 (RNS Number: 2679S) (the "Announcement"
, conditional on completion of the merger described in the Announcement, Vectura Group plc ("Vectura" intends that:.Andrew Derodra will be appointed as Chief Financial Officer of Vectura; .Frank Condella will be appointed as Vice Chairman of Vectura; . Thomas Werner will be appointed as a non-executive director of Vectura.Further to the Announcement, Vectura confirms the following information in respect of the proposed future Board members pursuant to paragraph 9.6.13(1) of the Listing Rules of the UK Listing Authority: Current and past directorships;Andrew Derodra .Skyepharma plc (current) Tate & Lyle International Finance plc (past);Frank Condella Skyepharma plc (current); Juniper Pharmaceuticals Inc. (current);Thomas Werner Skyepharma plc (current); Basilea Pharmaceutica Ltd (current); Medigene AG (past) 4SC AG (past) No further information is required to be disclosed in respect of Andrew Derodra, Frank Condella or Thomas Werner under paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.-Ends- Enquiries Vectura Group plc +44 (0)1249 667700Karl Keegan, Chief Corporate Development Officer Citigate Dewe Rogerson +44 (0)20 7638 9571David Dible / Mark Swallow About VecturaVectura is a leading independent inhaled device, formulation, development and specialist commercial business focusing on the development of pharmaceutical therapies for the treatment of airways diseases. Vectura has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Roxane Laboratories, Inc., Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company. Vectura develops products for airways diseases helping airways disease patients to improve their lives through uniquely applied insight and excellence in inhaled device engineering, formulation technology, product development and specialist commercialisation. For further information, please visit Vectura's website at www.vectura.com. Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.This information is provided by RNSThe company news service from the London Stock Exchange END RDNEAKDAALEKEFF
dave297
30 Mar 2016
Flutiform RNS today relating to the application by Mundi for a potential extension of the use of Flutiform in Europe .More positive newsflow to either make the merger more attractive or us more attractive to other suitors,some of whom must have been running their slide rules over our numbers & potential
raptor66
25 Mar 2016
Re: VEC is all ready in top 250 Correction, after the merger Vec will stay in ftse 350, just move up few notches.[link]
raptor66
25 Mar 2016
Re: VEC is all ready in top 250 Wishful thinking, Vec is actually part of ftse 350. Maybe after the merger it may get into ftse 250 club.[link]
dave297
24 Mar 2016
Re: VEC is all ready in top 250 Ta Dave-didn't think you could make the top 250 with such a low market cap.I amend my projection to the FTSE 100 then
d gaser
24 Mar 2016
VEC is all ready in top 250 Dave just thought you should know, VEC is all ready in the top 250 companies' in the UK, and in the top 10 riser's for today . BE HAPPYDAVE FTSE 250 - RisersFidessa Group (FDSA) 2,403.00p 2.91%Euromoney Institutional Investor (ERM) 897.00p 2.34%Hikma Pharmaceuticals (HIK) 1,903.00p 1.98%Circassia Pharmaceuticals (CIR) 265.10p 1.88%Riverstone Energy Limited (RSE) 811.00p 1.57%Melrose Industries (MRO) 350.10p 1.54%Regus (RGU) 311.00p 1.30%Vectura Group (VEC) 160.20p 1.26% ( this is us ) JD Sports Fashion (JD.) 1,119.00p 1.18%Jimmy Choo (CHOO) 132.50p 1.15%FTSE 250 - FallersRenishaw (RSW) 1,858.00p -9.32%Mitie Group (MTO) 240.70p -8.96%Kaz Minerals (KAZ) 164.80p -7.15%Tullow Oil (TLW) 197.60p -6.40%Countrywide (CWD) 365.40p -5.73%Ophir Energy (OPHR) 79.35p -4.28%Aberdeen Asset Management (ADN) 259.50p -4.03%Weir Group (WEIR) 1,070.00p -3.86%Vedanta Resources (VED) 308.00p -3.75%Petrofac Ltd. (PFC) 878.00p -3.68%
dave297
23 Mar 2016
Re: On reflection 33%,with Aviva s 4.5% (I think it was Aviva)-but they can,presumably change their minds
Looking for growth
23 Mar 2016
Re: On reflection They hope to complete 3rd quarter 2016. So vote will be around July. They have 28 per cent already undertaken.
MetalMuppet
22 Mar 2016
Re: On reflection also 2.79x156p VEC share price is still more than current SKP price by around 2%, so any weakness could still be worth buying some more SKP.Does anyone know the timescale for the merger?
Looking for growth
22 Mar 2016
Re: On reflection Dave basically there are 3 outcomes:-1. You are correct and Vec produce a nice set of results boasting the price all round.2. Results are average 3. Results are poor.If 1 above then that's fine. If 3 above I suspect the merger will be voted out by SKP shareholders. Which should also see our price increase after the vote is confirmed.If 2 then what happens becomes less predictable. As a result I think risk/reward favours buying a few more SKP, as I agree with you that 1 is most likely. We are protected against 3 to some extent in that we can vote against the merger.2 is probably the worst outcome, and I would review my position if that was the case.As such I topped up yesterday with a few more.LFG
dave297
22 Mar 2016
On reflection Our Board must have considered the Vec proposition very carefully & with view to Vecs year end ( Finals due soon)they must be aware that Vec have performed very well,possibly exceeding expectations & they must also have reviewed in detail Vecs pipeline & concluded it to have excellent prospects.On paper we look to be the stronger partner ( turnover,profits,cash flow,bank balance) & yet we have still accepted the minority role ,with about 40%of the enlarged group.The expectation must be that by the time the merger concludes the enlarged will qualify for inclusion in the 250,bringing with it more II support & more tracker fund investment & there must be a fair chance of the Vec SP reaching or exceeding 200p,resulting in about 560p for us,particularly if the newsflow from Vec & Skp is expected to be very positive over the coming months.I will now definitely take 100% shares in Vec & finalised I may buy more Skp on any weakness in our Sp before finalisation of the merger
Chicken Lips
21 Mar 2016
Re: MERGER Thanks DkokIt does seem that the sum of the total parts is greater than the two independent units.Combined revenues of 153 Million and profits of 50.5 and growing. The VEC results which have been trailed as a potential game changer already will be more than interesting - however I am down on the recent and 'strange', dramatic sp fall that has ripped through my VEC profit.I will hold about 15,000 shares in the combined company. I think the make up of the board is a good start - the enlarged company will be run by James Ward-Lilley, Vectura chief executive and a former senior AstraZeneca executive - sounds like the right person and the synergies, cost savings are also crucial.Mr Condella (Deputy Chief) said:The merger of Skyepharma and Vectura is a highly synergistic, value-enhancing transaction that will establish an industry leader in the development of inhalation products.its the 'earnings enhancing' no figure thats a bit worrying if this has been thought out on paper, surely there is a ball park figure for the deal:'Ventura predicted the deal would be earnings-enhancing in its first year, with projected annual pre-tax synergies of £10m by 2018'. (Both Quotes FT)I think I will hold to see what happens to the bigger VEC?SKP? business. Which I assume will trade as VEC. Prefer Skyepharma it has a 1960's summer of love branding.Will be watching the RNS, but all seems calm and this seems to be being seen as broadly positive by the markets.
dkok
21 Mar 2016
Re: MERGER CLI think that the Merger possibly came as a bit if a surprise to a few people, possibly including the II's involved in both companies.Broker forecasts for SKP are currently in the $£60-480p region but that was based on the previous years results. The final results announced last week would have Brokers' analysts reviewing their targets and I would expect they would have been increasing targets to 540-580p based on the results.In a similar vein, the Brokers forecasts and targets for VEC seem to be in the 280-280p range, a significant uplift from current chare price, and with their results due in a couple of months, these would have again been subject to review.What we now have is a potentially different animal, a combined drugs delivery company with complementary skils and products, and with major partners and clients, with less direct competition between businesses, and with a combined potential which I would suggest is greater than the sum of the parts.I think it will take a little while for the analysts to review all this and determine what the likely values will be, and assuming that the merger is successful, for the two businesses to successfully integrate. Looking at the way they are proposing to form the BoD, there seems to be a very sensible route forward being taken, with Peter Grant going, but with the SKP CFO taking over the finances, so the new board will be constituted from a focused group from each company, but avoiding the old problem with integration of businesses in trying to form an enlarged board with all members of both companies still on it. This always leads to problems as there becomes faction fights from the respective camps, but this route is not being proposed here, and what will come out of it is a single BoD made up of parts of each company, who should be focussed on achieving success for the newly enlarged company. Peter Grant and his BoD has done an excellent job with SKP over the last few years, and he and they must see some very clear benefits to consider doing wat they are proposing, particularly as PG is effectively losing his job as a result (no doubt with a good pay-off so I am not weeping for him), but it shows a high degree of confidence in the enlarged entity to effectively give up the SKP name and all the work that they have done in turning it around.I am going to vote for and to take all shares with no cash. Hopefully most will do this so that the enlarged company retains as much cash within the business as possible.The market at the moment certainly seems to be valuing the VEC side of shares higher than SKP, so I don't think that the SKP shareprice will outstrip it, in fact, buying SKP shares is currently an effective way of increasing your VEC shareholding at a discount tot he current VEC price.GLTAdkok
Chicken Lips
21 Mar 2016
Re: MERGER Thanks. Though they might but SKP seemed to have a headwind last week.
MetalMuppet
21 Mar 2016
Re: MERGER CL,I guess with the offer in place the share prices are going to be somewhat linked, not sure SKP will go to 450p unless VEC share price rises as well.Metal.
